BioSpace News Archive

Topline results on the analgesic efficacy of TLC590 for postsurgical pain management following the hard tissue surgery are expected in mid-2020

CareLight Solutions is proud to now be offering a complete line of industry-leading Light Therapy products to the public.

Mitchael Freeman, COO of Ocutrx Vision Technologies, LLC, a California-based technology startup developing a state-of-the-art augmented reality headset, this week delivered a forward-looking high-tech AR architecture presentation on the evolution of wearables in the healthcare space at the Medical Design & Manufacturing West Conference in Anaheim.

Regenexx, the world’s largest, cohesive physician group dedicated to practicing advanced orthobiologics and the first to use stem cells in the treatment of many orthopedic injuries, is celebrating its 15th year since inception.

Inteliquet, a leading provider of intelligent technology, advanced insights, and expertise for clinical research, patient treatment and translational medicine, announced findings of a survey aimed at examining adoption of real-world data in healthcare and clinical research.

Cybin, Canada’s premier medicinal mushroom life sciences company with a core focus on advancing psilocybin research and intellectual property is pleased to announce a strategic partnership with the Toronto Centre for Psychedelic Science.

CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced that its biorepository in Rostock, Germany, which they believe holds the largest diversity of positive tested cases in the field of inherited rare diseases, has received accreditation from the College of American Pathologists (CAP).

Caris Life Sciences®, today announced the publication of new data in Nucleic Acids Research, illustrating that use of the Company’s proprietary ADAPT Biotargeting System™ can lead to the identification of differences in protein expression patterns between exosomes from two related prostate cancer cell lines, vertebral cancer of the prostate (VCaP) and lymph node cancer of the prostate (LNCaP).

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences:

Illumina, Inc. announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.